While all forms of weight loss, including treatment with GLP-1 medications, results in some degree of lean body mass and skeletal muscle loss, it's crucial to understand the broader context
For weight management, some patients may use the medication until achieving their goal weight and then attempt to maintain weight loss through lifestyle modifications alone, while others may require continued treatment to prevent weight regain
Novel method for fabrication of skeletal muscle construct from the C2C12 myoblast cell line using serum-free medium AIM-V
Additionally, it activates calcitonin receptor and receptor activity-modifying protein complexes
Study period 1/1/2017 to 7/1/2025 Study population: inclusion Patients with A GLP-1 prescription for at least 90 days At least five pounds of weight loss while on the GLP-1 A weight reading between 30 days prior through 3 days after starting the GLP-1 A weight reading within 30 days of stopping the GLP-1 At least one weight reading 1 to 24 months following end of the GLP-1 Study population: exclusion Thyroid conditions (ever): ICD-10-CM E03*or E05* Eating disorders (ever): ICD-10-CM F50* Pregnancy within a year before GLP-1 start through GLP-1 stop Censoring Other weight loss medication or restart of GLP-1 Amputation Bariatric surgery Pregnancy that started in period after GLP-1 was stopped Outcomes Percent of weight change relative to initial weight loss after end of GLP-1 treatment GLP-1 A medication with a simple generic of semaglutide, liraglutide, or tirzepatide
A Patient Health Questionnaire-9 score of 15 at screening
